For Immediate Release

ASX Annoucement

19 August, 2025
Melbourne, Australia

Results Presentation

for the full year ended 30 June 2025

CSL Limited (ASX:CSL; USOTC:CSLLY)

Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer shortly. The live briefing will be webcast and can be viewed at https://edge.media-server.com/mmc/p/eaiq47e2/

Please note that this link will expire after the webcast concludes.

A recording of the webcast will be made available later in the day at:
https://investors.csl.com/investors/financial-results-and-information

Authorised for lodgement by:

Fiona Mead
Company Secretary

Investor Relations

Chris Cooper
Head, Investor Relations
CSL Limited
P: +61 455 022 740
E: chris.cooper@csl.com.au

Media Relations

Brett Foley
Communications
CSL Limited
P: +61 461 464 708
E: media@csl.com.au

CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000

2025 Full Year Results

19 August 2025

Paul McKenzie
Chief Executive Officer
& Managing Director

Joy Linton
Chief Financial Officer



IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, **CSL**) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (**ASX**), available at www.asx.com.au. This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements . Factors that could cause actual results to differ materially include: the success or otherwise of CSL’s research and development activities; factors affecting CSL’s ability to successfully market and sell new and existing products, including decisions by regulatory authorities regarding approval of CSL’s products and regarding label claims, competitive developments affecting CSL’s products, and trade buying patterns; factors affecting CSL’s ability to collect plasma, and difficulties or delays in manufacturing; legislation or regulations affecting the manufacturing, distribution, pricing, or reimbursement of CSL’s products, market access for CSL’s products, environmental protection matters, or tax; litigation or government investigations; fluctuations in interest and currency exchange rates; acquisitions or divestitures; and CSL’s ability to protects its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

CEO Overview

Paul McKenzie
CEO & Managing Director

Agenda

1 Introduction

2 FY25 Business Performance

3 Financials

4 Strategic Transformation
Intent to Demerge CSL Seqirus

5 Outlook and FY26 Guidance

6 Q&A

CSL

Agenda

1	**Introduction**
2	FY25 Business Performance
3	Financials
4	Strategic Transformation Intent to Demerge CSL Seqirus
5	Outlook and FY26 Guidance
6	Q&A

CSL

Strong performance in FY25[1]

Revenue +5%
NPATA[2,3] +14%
NPAT[3] +17%

Leverage 1.8x
FCF[6] +58%
Dividend[6] +12%*



Revenue Growth[1]

CSL Behring	+6%
CSL Seqirus	+2%
CSL Vifor	+8%

* Final Dividend

Major initiatives announced to drive further value creation

Transformation initiatives

- Distinctive Portfolio Development & Commercialisation operating model
- Targeting annual pre-tax savings >$500m by the end of FY28
- Disciplined reinvestment of savings in high priority growth opportunities

Intent to demerge CSL Seqirus

- Substantial ASX-listed entity in FY26

Capital management

- Multi-year share buyback reintroduced in FY26

Agenda

1	Introduction
2	**FY25 Business Performance**
3	Financials
4	Strategic Transformation Intent to Demerge CSL Seqirus
5	Outlook and FY26 Guidance
6	Q&A

CSL Behring

Revenue $11,158m +6%[1]

Therapy	Revenue ($m)	Change[1]
Ig	6,064	+7%
Albumin	1,297	+7%
Haemophilia	1,488	+13%
Hereditary Angioedema	760	+4%
Peri-Operative Bleeding	913	(10%)

Highlights

Ig
- PRIVIGEN® / INTRAGAM®+8%, HIZENTRA® +6%
- Six months of Medicare Part D Reform
  - ~($100 million) impact
- Robust demand across all core indications

Albumin
- Solid growth driven by China

Haemophilia
- IDELVION® remains standard of care, +10%
  - Leadership position in US, key EU markets and Japan
- Increased uptake of HEMGENIX® in US and Europe

Hereditary Angioedema
- First sales of ANDEMBRY® in US and other key markets
- HAEGARDA® stable

Peri-Operative Bleeding
- KCENTRA® (16%)
  - Sequential growth in second half
- Progress on label expansions for KCENTRA® and RiaStap®

Major Brands

- Ig: Hizentra® Immune Globulin Subcutaneous (Human) 20% Liquid; privigen® Immune Globulin Intravenous (Human), 10% Liquid
- Albumin: AlbuRx®
- Haemophilia: HUMATE-P® Antihemophilic Factor/von Willebrand Factor Complex (Human); IDELVION® Coagulation Factor IX (Recombinant), Albumin Fusion Protein; Haemate® P 1000; HEMGENIX® etranacogene dezaparvovec-drlb
- Hereditary Angioedema: ANDEMBRY® garadacimab-gxii; HAEGARDA® C1 Esterase Inhibitor Subcutaneous (Human); BERINERT® C1 Esterase Inhibitor, Human
- Peri-Operative Bleeding: KCENTRA® Prothrombin Complex Concentrate (Human) Urgent Warfarin Reversal; RIASTAP® Fibrinogen Concentrate

CSL Seqirus

Revenue $2,166m +2%[1]

Therapy	Revenue ($m)	Change[1]
Egg Based	116	(17%)
Cell Culture	474	(12%)
Adjuvanted Egg	901	(14%)
Pre-Pandemic	197	+235%
Pandemic	179	+3%
Other (inc in-license)	299	+69%

Highlights

- Revenue impacted by decline in US vaccination rates
- Momentum in US paediatric segment
- Received preferential recommendation for FLUAD® in Germany and France for 60+
- Positive ACIP universal influenza recommendation
- Seasonal influenza business expected to stabilise in FY26
- Award of over 90% of H5 avian flu contracts globally
- Reservation agreements in place with 20 countries
- Includes revenue from COVID vaccine distribution partner in Japan

Major Brands

INFLUENZA VACCINE afluria QUADRIVALENT

Influenza Vaccine FLUCELVAX QUADRIVALENT

FLUAD®

For personal use only

CSL Vifor

Revenue $2,234m +8%[1]

Therapy	Revenue ($m)	Change[1]
Iron	1,034	+1%
Nephrology *Dialysis*	871	+10%
Nephrology *Non-Dialysis*	267	+34%

Highlights

- Global volume growth
- Impacted by generic competition in EU
- Increased FERINJECT® sales in China

- VELPHORO®
  - Strong growth from inclusion in TDAPA
- MIRCERA®
  - Market leader in US
- KAPRUVIA®
  - Strong performance in European markets

- TAVNEOS®
  - Excellent uptake in all launch markets
- FILSPARI®
  - Successful launches in Germany, Austria and Switzerland

Major Brands

ferinject® ferric carboxymaltose; Venofer® iron sucrose injection, USP; MIRCERA®[a]; VELPHORO®; Retacrit® epoetin alfa-epbx[b]; KAPRUVIA®; FILSPARI®[c]; Veltassa®; TAVNEOS™ (avacopan)[d]

a. Licensed from F. Hoffman-La Roche AG; b. Licensed from Pfizer Inc.; c. Rights to EU, AUS&NZ and certain other countries licensed from Travere Therapeutics, Inc. .; d. Rights to EU, UK, Japan and certain other countries licensed from ChemoCentryx, Inc., a wholly owned subsidiary of Amgen, Inc.

Agenda

1	Introduction
2	FY25 Business Performance
3	**Financials**
4	Strategic Transformation Intent to Demerge CSL Seqirus
5	Outlook and FY26 Guidance
6	Q&A

CSL

Financials

Joy Linton **CFO**

NPATA[2,3]



	FY24 Rep	FY25 @CC	Change %[1]
NPATA	**$2,907m**	**$3,303m**	**+14%**
Acquired intellectual property amortisation	($301m)	($364m)	
Other acquisition and disposal adjustments	($84m)	$30m	
Tax	$61m	$57m	
NPATA Attributable to NCI	$131m	$191m	
NPAT	**$2,714m**	**$3,217m**	**+19%**
NPAT Attributable to NCI	($72m)	($131m)	
NPAT to CSL shareholders	**$2,642m**	**$3,086m**	**+17%**

CSL

For personal use only

CSL Group
Financial Highlights

US$ Millions	FY24 Rep	FY25 Rep	FY25 at CC[1]	Change %[1]
Total Revenue	**14,800**	**15,558**	**15,587**	**5%**
Gross Profit[4]	**8,006**	**8,443**	**8,509**	**6%**
GP %[4]	*54.1%*	*54.3%*	*54.6%*	
Sales & Marketing[4]	(1,556)	(1,616)	(1,619)	(4%)
Operating Result[4]	**6,450**	**6,827**	**6,890**	**7%**
R&D[4]	(1,428)	(1,359)	(1,358)	5%
G&A[4]	(825)	(1,000)	(945)	(15%)
Net Interest Expense	(437)	(410)	(409)	6%
NPATA[3]	**2,907**	**3,219**	**3,303**	**14%**
ETR %	19.2%	15.9%	16.4%	
ROIC	10.5%	11.5%		
Cashflow From Ops	2,764	3,561		29%[Y]
Free Cashflow	1,819	2,866		58%[Y]
Capex	(847)	(636)		25%[Y]
NPATA EPS[3] ($)	6.02	6.65		10%[Y]
DPS ($)	2.64	2.92		11%[Y]

Y. At reported currency
Capital Expenditure for Property, Plant & Equipment

R&D

- Prioritising growth opportunities
- FY26 guidance: ~US$1.35b

G&A

- FY25 in line with guidance
- FY26 guidance: ~US$1.0b

Finance

- Balance Sheet continued to de-lever in FY25

Tax

- FY26 guidance: 18-20% (excl. FX)

Cashflow

- Cashflow from Operations: strong improvement driven by growth in business and working capital management
- Strong increase in free cashflow due to continued reduction in capex

Capex

- FY26 guidance: ~$800m +/- $100m
- Expanding Ig capacity in US over mid-term

CSL

Segment
Financial Highlights

CSL Behring

US$ millions reported	FY24	FY25	Change % at CC[1]
Sales	**10,334**	**10,930**	**6%**
Other Revenue	274	228	(16%)
Total Revenue	**10,608**	**11,158**	**6%**
Gross Profit[4]	5,275	5,641	8%
GP %[4]	*49.7%*	*51.0%[1]*	
Sales & Marketing[4]	*(903)*	*(937)*	(4%)
Operating Result	**4,372**	**4,704**	**9%**
Operating Segment %[4]	*41.2%*	*42.2%*	

Continued Gross Margin Improvements

Key Contributors

CPL Reduction
- Optimise donor fees
- RIKA and I-Nomi
- Network efficiencies

New Products
- ANDEMBRY®
- HEMGENIX®
- HIZENTRA® PFS

ASP Mix Shift
- HIZENTRA® v PRIVIGEN®
- Geographic mix

Ig Yield Improvements
- Horizon 1

Scale & Efficiency Measures
- Increased volume
- Variable v fixed costs
- Manufacturing efficiencies

Excludes potential benefits of Horizon 2 initiatives

Illustrative only

CSL

Segment

Financial Highlights

CSL Seqirus

US$ millions reported	FY24	FY25	Change % at CC[1]
Sales	**1,896**	**1,906**	**-**
Other Revenue	232	260	11%
Total Revenue	**2,128**	**2,166**	**2%**
Gross Profit[4]	1,318	1,257	(5%)
GP %[4]	*61.9%*	*58.1%[1]*	
Sales & Marketing	*(196)*	*(230)*	(19%)
Operating Result[4]	**1,122**	**1,027**	**(9%)**
Operating Segment %[4]	*52.7%*	*47.4%*	

CSL Vifor

US$ millions reported	FY24	FY25	Change % at CC[1]
Sales	**2,029**	**2,199**	**8%**
Other Revenue	35	35	-
Total Revenue	**2,064**	**2,234**	**8%**
Gross Profit[4]	1,413	1,545	9%
GP %[4]	*68.5%*	*69.2%[1]*	
Sales & Marketing	*(457)*	*(449)*	*2%*
Operating Result[4]	**956**	**1,096**	**14%**
Operating Segment %[4]	*46.3%*	*49.1%*	

CSL

Share buyback reintroduced



- Strong cash flow has significantly de-levered the Balance Sheet
- Sufficient capacity to support investment in growth opportunities
- Multi-year, on-market share buyback as part of refreshed capital management strategy - A$750m (~US$500m) in FY26, expected to progressively increase over the medium-term
- Target leverage range of 1.5x – 2.0x from FY26

CSL

Agenda

1 Introduction

2 FY25 Business Performance

3 Financials

4 Strategic Transformation
Intent to Demerge CSL Seqirus

5 Outlook and FY26 Guidance

6 Q&A

Strategic transformation to deliver value

Operating model complexity has increased with growth, against a volatile macro environment

Clear opportunity to improve R&D and commercial productivity and build on our operational efficiencies

Annual pre-tax savings of **>$500m** by the **end of FY28***

Distinctive operating model

Optimised R&D expenditure

↓ Footprint from 11 sites to 6

Faster time-to-market

Up to 15% headcount reduction

Closure of 22 underperforming plasma centres in FY26

One-off pre-tax restructuring costs
$700-770m ($400-450m cash) in FY26**

Disciplined reinvestment of savings in high priority growth opportunities

A refocused CSL will…

Direct savings to accelerate clinical pipeline and priority programs

Be lean and agile

Streamline corporate functions and drive additional revenue growth opportunities

Simplify decision making

*The initiatives are expected to drive annualised cost savings of $500-550 million progressively over the next three years, with the majority achieved by the end of Financial Year 2027.

**A further ~$100 million cash impact is expected in Financial Year 2027

Agenda

1	Introduction
2	FY25 Business Performance
3	Financials
4	Strategic Transformation **Intent to Demerge CSL Seqirus**
5	Outlook and FY26 Guidance
6	Q&A

CSL

Intention to demerge CSL Seqirus to CSL shareholders

- CSL Seqirus to be demerged, creating an ASX listed global vaccine leader
- Company to be chaired by Mr Gordon Naylor
- The demerger will be subject to third party consents, regulatory approvals and CSL will conduct a voluntary shareholder vote
- Targeting completion before the end of financial year 2026

Strong strategic rationale to enhance shareholder value

Reduces complexity, making businesses more agile and efficient to manage

Reinvigorates focus on core differentiating capabilities

Enables acceleration of transformation and efficiency projects

Autonomy to set strategic direction and capital allocation

Capitalise on potential opportunities that may arise in dynamic markets

Two global leaders in healthcare

CSL

- Global #1 in ~$38bn plasma protein therapies industry
- Global #1 in ~$5bn iron industry
- Leading manufacturer of plasma-derived therapies, utilising a best-in-class, global network of plasma centers
- Leading market positions in rare diseases
- Long track record of delivering value to shareholders

$13.4bn FY25 Revenue	$5.8bn* FY25 Operating Result

FY25 Revenue by Therapy Group



Seqirus

- Global #2 in ~$7bn influenza vaccine industry with attractive long-term fundamentals
- Highly differentiated and market leading portfolio
- Strong and differentiated clinical pipeline
- Deep Australian heritage, including supply of products of national significance

$2.2bn FY25 Revenue	$1.0bn* FY25 Operating Result

FY25 Revenue by Therapy Group



Note:
** Operating result does not include allocation of group costs.*
***Other comprises: In License, Pre-Pandemic, Pandemic Res Fees and Other Income.*

Agenda

1	Introduction
2	FY25 Business Performance
3	Financials
4	Strategic Transformation Intent to Demerge CSL Seqirus
5	**Outlook and FY26 Guidance**
6	Q&A

CSL

Outlook

CSL Behring

- Robust patient demand across multiple areas of high unmet need
- HIZENTRA® to grow strongly
- PRIVIGEN® impacted by tender losses in UK and Mexico
- Building on positive ANDEMBRY® launch momentum
- Horizon 1 and 2 yield initiatives progressing to plan
- Consistent annual increases in Gross Margin through mid-term

CSL Vifor

- Well-positioned for iron competition
- Nephrology launch momentum
- Commercial and medical integration with CSL Behring

CSL Seqirus

- Seasonal influenza revenue to stabilise
- Substantially lower contribution from avian influenza and COVID-19
- Leverage differentiated portfolio
- Significant geographic launch opportunities (Germany, France, Korea)

CSL Group

- Reduce fixed cost in R&D and drive pipeline productivity
- Embed distinctive Portfolio Development & Commercialisation model
- Optimise activities across plasma network
- Streamline corporate costs
- Recommence multi-year share buyback
- Potential sectoral tariffs unlikely to impact strategic initiatives

FY26 Guidance[7]

Revenue Growth

~ 4 - 5% @CC[1]

NPATA Growth

(excl. restructuring cost[5])

~ 7 – 10% @CC[1,3] to ~$3.45 – $3.55b @CC[1,3]

Notes:

- *Group revenue guidance excluding an incremental ~$100m IRA Part D reform impact ~ 5 – 6% @CC[1]*
- *NPATA guidance excluding an incremental -$85m post-tax impact from Part D Reform ~ 10 – 13% @CC[1,3] ~$3.54 - $3.64b @ CC[1,3]*
- *FY26 FX impact estimated to be a tailwind of ~$60m if current rates remain unchanged for the remainder of the Financial Year*

Agenda

1	Introduction
2	FY25 Business Performance
3	Financials
4	Strategic Transformation Intent to Demerge CSL Seqirus
5	Outlook and FY26 Guidance
6	**Q&A**

CSL

CSL Contacts

Chris Cooper
Investor Relations
+61 455 022 740
chris.cooper@csl.com.au

Bernard Ronchi
Investor Relations
+61 431 060 964
bernard.ronchi@csl.com.au

Jimmy Baker
Investor Relations
+61 450 909 211
jimmy.baker@csl.com.au

Notes

(#) Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than US Dollars, at the rates that were applicable to the prior year (translation currency effect); b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior year (transaction currency effect); and c) by adjusting for current year foreign currency gains and losses. The sum of translation currency effect, transaction currency effect and foreign currency gains and losses is the amount by which reported net profit is adjusted to calculate the operational result.

General Disclaimer Non-IFRS

There are references to IFRS (International Financial Reporting Standards) and non-IFRS financial information in this document. Non-IFRS financial measures are financial measures other than those defined or specified under any relevant accounting standard and may not be directly comparable with other companies' information. Non-IFRS financial measures are used to enhance the transparency and comparability of a financial report. Non-IFRS financial information should be considered in addition to, and is not intended to be a substitute for, IFRS financial information and measures. Non-IFRS financial measures are not subject to audit or review.

Summary NPAT attributable to members of parent entity

Reported net profit after tax	$3,002m
Currency effect	$84m
Constant currency net profit after tax*	**$3,086m**

Average exchange rates for major currencies for full year ended 30 June 2025/ 30 June 2024 include: USD/EUR (0.92/0.92), USD/AUD (1.55/1.52), USD/CHF (0.87/0.89), USD/CNY (7.21/7.22) and USD/GBP (0.77/0.79).

Summary NPATA[2] attributable to members of the parent entity	US$m
Reported net profit after tax	3,002
Amortisation of acquired intellectual property	295
Net gain on business disposals	(30)
Income tax credit on above adjustments	(48)
NPATA[2] attributable to members of the parent entity	3,219
Currency effect attributable to members of the parent entity	84
Constant Currency# NPATA[2] attributable to members of the parent entity	**3,303**

Summary Revenue

Reported revenue	$15,558m
Currency effect	$29m
Constant currency revenue*	$15,587m

*Constant currency net profit after tax and constant currency sales have not been audited or reviewed in accordance with Australian Auditing Standards.

Footnotes

1. Percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail
2. NPATA is defined as the statutory NPAT before impairment and amortisation of acquired IP and non-recurring items from business acquisition and disposals
3. Attributable to the shareholders of CSL Limited
4. Underlying results have been adjusted to exclude impairment and amortisation of acquired IP and non-recurring items from business acquisition and disposals
5. Pre-tax restructuring costs $700-770m in FY26
6. Reported FX rates
7. Does not incorporate the impact of the potential CSL Seqirus demerger

NPATA to NPAT FY26 outlook

NPATA (excl. restructuring costs) to NPAT adjustments, attributable to:	Group		CSL shareholders (post tax)	
	FY26 Outlook	**FY25 at CC**	**FY26 outlook**	**FY25 at CC**
Restructuring costs	700-770		560-630	
Income tax on restructuring costs	(140)-(150)			
Amortisation of acquired intellectual property	370+/- 10%	364	260 +/- 10%	251
Net gain on disposal	-	(30)	-	(33)
Income tax on above adjustments	(60) +/- 10%	(57)	-	-
Total	**900 +/- 10%**	**277**	**850 +/- 7%**	**217**

For personal use only

Appendix

Appendix A
CSL Behring – Key Products

CSL Behring	Therapy Group	Sales $m	Change[1] %
Privigen	IVIG	3,904	8%
Hizentra	SCIG	2,078	6%
Albumin	Albumin	1,297	7%
Idelvion	Haemophilia	853	10%
Kcentra	Peri-operative bleeding	592	(16%)
Haegarda	HAE	490	-
Berinert	HAE	248	3%
Haemocomplettan	Peri-operative bleeding	242	6%
Humate	Haemophilia	202	10%
Haemate	Haemophilia	138	18%
Hemgenix	Haemophilia	92	189%

FY25 Revenue By Therapy Group $m



Appendix B

CSL Seqirus & CSL Vifor – Key Products

CSL Seqirus	Therapy Group	Sales $m	Change[1] %
Fluad	Adjuvanted	901	(14%)
Flucelvax	Cell culture	474	(12%)
Afluria	Egg-based	111	(21%)

CSL Vifor	Therapy Group	Sales $m	Change[1] %
Ferinject/Injectafer	Iron	766	-
Mircera	Nephrology: Dialysis	567	(8%)
Velphoro	Nephrology: Dialysis	258	137%
Venofer	Iron	172	(2%)
Veltassa	Nephrology: Non Dialysis	144	4%
Tavneos	Nephrology: Non Dialysis	112	86%
Maltofer	Iron	91	11%

FY25 Revenue By Therapy Group $m



CSL

R&D Portfolio Highlights – FY25

For personal use only

Immunoglobulins

- HIZENTRA® PFS 50mL
  - JP submission complete
  - EU approval complete
- Horizon 2
  - Toxicology package complete
  - Process robustness package complete

Haematology

- HEMGENIX® Japan Phase III last patient in complete
- AFSTYLA® China Phase III first patient in complete
- RiaSTAP® AFD
  - Phase III first patient in complete
  - US submission complete
  - Improved fibrinogen manufacturing process EU approval received
- CSL889 (Hemopexin) VOC in SCD Phase II first patient in (July)

Cardiovascular & Renal

- Clazakizumab (ESKD)
  - Enrolment ongoing
  - FDA Phase III DAP submitted
- FILSPARI® (Sparsentan) IgAN Full EU approval complete

Transplant & Immunology

- ANDEMBRY® (Garadacimab; Anti-FXIIa) HAE
  - AU, JP, EU, UK, Switzerland & US approved
- CSL964 in aGvHD
  - Treatment Data presented at TCT Feb 25
  - Phase 3 prevention study futility passed

Vaccines

- CSL403 (aTIVc)
  - UK & EU submissions complete
- QIV to TIV Transition US, EU, UK approval complete
- KOSTAIVE® sa-mRNA (COVID)
  - JP launch – EU marketing authorization - UK submission

Discontinued Programs

- KCENTRA® Trauma
- HIZENTRA® Dermatomyositis
- HIZENTRA® POTS
- Clazakizumab AbMR

Abbreviations: *AFD – Acquired Fibrinogen Deficiency; aTIVc - Adjuvanted Cell-based Trivalent Influenza Vaccine; DAP – Diversity Action Plan; EU – Europe; FDA – Food & Drug Administration; HA – Health Authorities; HAE – Hereditary Angioedema; JP – Japan; IgAN – Immunoglobulin A Nephropathy; PFS – Pre-Filled Syringe; POTS - Postural Orthostatic Tachycardia Syndrome; PK – Pharmacokinetic; PR – Prolonged Release; QIV – Quadrivalent Influenza Vaccine; RNA – Ribonucleic Acid; sa-mRNA – Self-Amplifying messenger RNA; TCT - Transplantation and Cellular Therapy; TIV- Trivalent Influenza Vaccine; UK - United Kingdom; US – United States; VOC – Vaso-occlusive Crisis.*

CSL